Skip to content
WeighLab
Menu

Evidence review

Compounded vs Brand-Name GLP-1: The Real Cost Difference

Wegovy and Zepbound list near $1,000+/mo; compounded semaglutide and tirzepatide run roughly $65–$349. What you trade for the gap, in dollars and oversight.

By The WeighLab Bench, Tools & Data Desk

The price gap between brand-name and compounded GLP-1 medication is the widest in the whole category, and it is where most of the confusion lives. This guide lays out what each option actually costs, what the money buys, and where the trade-offs are — so you can decide on value rather than on whichever number you saw first.

The brand-name price: Wegovy and Zepbound

The FDA-approved brand-name options are Wegovy (semaglutide 2.4 mg), approved for chronic weight management in 20211, and Zepbound (tirzepatide), approved in 20232. Their manufacturer list prices sit in roughly the $1,000–$1,350-per-month range before insurance or manufacturer savings programs. If your insurance covers weight-management medication, your out-of-pocket cost can fall dramatically — sometimes to a modest copay. If it does not, that list price is what you face, and coverage for obesity medication remains inconsistent.

The compounded price: what telehealth actually charges

Compounded semaglutide and tirzepatide are prepared by compounding pharmacies and sold cash-pay through telehealth. Across the providers we track, disclosed monthly prices run from about $65 to $349 per month, depending on the molecule, the provider, and your dose — a fraction of brand-name list pricing. That is the entire reason the compounded market exists at this scale. You can model your own number in the cost calculators, and we break the ranges down in what compounded GLP-1 actually costs per month.

Same molecule, different regulatory status

Here is the part that matters. Brand-name and compounded products can use the same active ingredient — semaglutide or tirzepatide — and the efficacy evidence for those molecules is strong: semaglutide 2.4 mg drove about 15% mean weight loss in its pivotal trial3, and tirzepatide up to about 21% in its own4. But those trials studied the brand-name, FDA-approved products. Compounded versions are not FDA-approved, and the FDA does not verify the safety, effectiveness, or quality of compounded drugs5. The molecule may be the same on paper; the regulatory assurance is not. That is the real trade behind the price gap.

So what are you actually paying for?

Brand-name pricing buys FDA-verified manufacturing, a consistent supply chain, and — if you have coverage — the possibility that insurance absorbs most of the cost. Compounded pricing buys access at cash-pay rates most people can actually sustain month to month. Neither is automatically the "right" answer. The honest framing is: if your insurance covers a brand-name GLP-1, that is often both the safest and, net of coverage, the cheapest route. If it does not, compounded medication from a verifiable, LegitScript-certified pharmacy is what makes treatment affordable for many people — provided you understand what FDA approval you are giving up.

Do the year-one math, not the month-one math

Whichever side you land on, compare total annual cost, not the first sticker you see. For brand-name, that means confirming your actual copay after any savings program. For compounded, it means checking for teaser rates that step up after month one and adding dose-escalation costs — the full method is in the true monthly cost of GLP-1. Then rank your finalists on our provider reviews and settle it on the compare tool.

Frequently asked questions

Why is compounded semaglutide so much cheaper than Wegovy?

Compounded medication is cash-pay and not FDA-approved, so it skips brand pricing and coverage negotiation. Disclosed telehealth prices run roughly $65–$349 per month versus brand list prices near $1,000+.

Is compounded GLP-1 the same as the brand-name drug?

It can use the same active molecule, but compounded products are not FDA-approved and the FDA does not verify their safety, effectiveness, or quality. The molecule may match; the regulatory assurance does not.

Which is cheaper overall, brand-name or compounded?

If insurance covers a brand-name GLP-1, that route is often cheapest net of coverage. Without coverage, compounded medication is usually far more affordable month to month.

References

  1. U.S. Food and Drug Administration (2021). FDA Approves New Drug Treatment for Chronic Weight Management (Wegovy, semaglutide 2.4 mg). U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
  2. U.S. Food and Drug Administration (2023). FDA Approves New Medication for Chronic Weight Management (Zepbound, tirzepatide). U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
  3. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
  4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/35658024/
  5. U.S. Food and Drug Administration (2024). Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.